Related Experiment Video

Updated: Jun 2, 2026

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells
10:13

A Multiplexed Luciferase-based Screening Platform for Interrogating Cancer-associated Signal Transduction in Cultured Cells

Published on: July 3, 2013

Differential gene expression signatures between colorectal cancers with and without KRAS mutations: crosstalk between

Toshiaki Watanabe1, Takashi Kobunai, Yoko Yamamoto

  • 1Department of Surgery, Teikyo University School of Medicine, Itabashi-ku, Tokyo 173-8605, Japan. toshwatanabe@yahoo.co.jp

European Journal of Cancer (Oxford, England : 1990)
|May 3, 2011
PubMed
Abstract

Insights

KRAS mutations in colorectal cancer (CRC) create unique gene expression profiles. These findings reveal pathway crosstalk and inform anti-EGFR therapy strategies for KRAS mutant CRCs.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • KRAS mutation status is crucial for predicting response to anti-Epidermal Growth Factor Receptor (EGFR) therapies in colorectal cancer (CRC).
  • Understanding alterations in signaling pathways beyond KRAS is essential for comprehensive treatment strategies.

Purpose of the Study:

  • To investigate differences in gene expression signatures between CRCs with and without KRAS mutations.
  • To identify novel signaling pathways affected by KRAS mutations in colorectal cancer.

Main Methods:

  • Analysis of gene expression profiles from 113 primary CRC samples using Human Genome GeneChip array U133.
  • KRAS mutational status determined by Peptide Nucleic Acid (PNA)-clamp real-time polymerase chain reaction (PCR) TaqMan assay.

Main Results:

  • KRAS mutations were identified in 31% of the CRCs analyzed.
  • A distinct gene expression signature comprising 30 differentially expressed genes was identified, enabling KRAS status prediction with 90.3% accuracy.
  • These differentially expressed genes are involved in KRAS, Wnt, NF-kappa B, and TGF-beta signaling pathways.

Conclusions:

  • KRAS mutant CRCs display a unique gene expression signature compared to wild-type KRAS CRCs.
  • Evidence of crosstalk between KRAS-mediated and other signaling pathways (Wnt, NF-kappa B, TGF-beta) was demonstrated in human CRC samples.
  • These findings necessitate consideration in developing chemotherapeutic strategies for anti-EGFR-refractory KRAS mutant CRCs.

More Related Videos

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans08:12

Identification of EGFR and RAS Inhibitors using Caenorhabditis elegans

Published on: October 5, 2020

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a superfamily...
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Small GTPases - Ras and Rho01:24

Small GTPases - Ras and Rho

Ras and Rho are small monomeric GTPases that act downstream of receptor tyrosine kinase (RTK) and regulate various cellular processes. These GTPases switch between active and inactive states by binding to guanine nucleotides.
Three regulatory proteins control their activity: